Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
NCT ID: NCT01021332
Last Updated: 2024-12-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1067 participants
INTERVENTIONAL
2010-04-26
2011-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Total Group
Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
oral
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
oral
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_CHAIR
Astellas Pharma Global Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Innsbruck, , Austria
Vienna, , Austria
Minsk, , Belarus
Minsk, , Belarus
Minsk, , Belarus
Antwerp, , Belgium
Edegem, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Liège, , Belgium
Hradec Králové, , Czechia
Ostrava, , Czechia
Pilsen, , Czechia
Roudnice nad Labem, , Czechia
Uherské Hradiště, , Czechia
Ústí nad Labem, , Czechia
Zd'ar Nad Sazavou, , Czechia
Colmar, , France
Montluçon, , France
Orléans, , France
Paris, , France
Paris, , France
Pierre-Bénite, , France
Bautzen, , Germany
Eisleben Lutherstadt, , Germany
Frankfurt, , Germany
Ganderkesee, , Germany
Hagenow, , Germany
Halle, , Germany
Hamburg, , Germany
Henningsdorf, , Germany
Hettstedt, , Germany
Koblenz, , Germany
Leipzig, , Germany
Leipzig, , Germany
Neustadt in Sachsen, , Germany
Radebeul, , Germany
Sachsen, , Germany
Trier, , Germany
Uetersen, , Germany
Avellino, , Italy
Catanzaro, , Italy
Palermo, , Italy
Treviglio, , Italy
Amsterdam, , Netherlands
Apeldoorn, , Netherlands
Doetinchem, , Netherlands
Maastricht, , Netherlands
Sneek, , Netherlands
Tilburg, , Netherlands
Winterswijk, , Netherlands
Bielsko-Biala, , Poland
Bydgoszcz, , Poland
Krakow, , Poland
Puławy, , Poland
Warsaw, , Poland
Więcbork, , Poland
Nitra, , Slovakia
Piešťany, , Slovakia
Prešov, , Slovakia
Skalica, , Slovakia
Trenčín, , Slovakia
Cardiff, , United Kingdom
Chorley, , United Kingdom
Liverpool, , United Kingdom
Northwood, , United Kingdom
Oxford, , United Kingdom
Reading, , United Kingdom
Sheffield, , United Kingdom
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on Astellas Clinical Study Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-001212-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
905-CL-057
Identifier Type: -
Identifier Source: org_study_id